Ensysce Biosciences Inc Dossier - Source-backed chat

Ensysce Biosciences Inc

ENSCNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.88

Intrinsic Value $0.31median of 2 methodsbased on filings through 31 Dec 2025

Market Price $0.40Price as of 1 Oct 2026

OvervaluedIntrinsic value is 23% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $7.8M

Enterprise Value $3.8M

Shares Outstanding 19.5M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Ensysce Biosciences is a clinical-stage biotech company developing highly innovative, abuse-resistant (TAAP platform) and overdose-protected (MPAR platform) opioid therapeutics. While its lead candidate PF614 is progressing through a pivotal Phase 3 trial and PF614-MPAR holds FDA Breakthrough Therapy designation, the company is facing a severe liquidity squeeze. With cash reserves down to $0.75 million and a stockholders' equity deficit as of Q1 2026, Ensysce is under a Nasdaq delisting warning and has initiated a formal review of strategic alternatives. The clinical promise is offset by high financing risks, making a 'Hold' recommendation appropriate until a strategic partnership or funding solution is secured.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$16.45

Mean target$16.45

High · most bullish analyst$16.45

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.10

Ensysce fails to regain compliance with Nasdaq's stockholders' equity requirement, leading to a delisting to the OTC markets. The strategic review does not yield a viable partnership or transaction, and the company is unable to secure additional capital, forcing a pause or termination of the pivotal PF614 Phase 3 trial due to insolvency.

Base CaseCentral scenario

$0.39

Ensysce continues to advance its clinical trials utilizing its $20 million convertible preferred stock facility and federal grants. The company submits a successful compliance plan to Nasdaq and receives an extension to regain compliance. Strategic review discussions progress slowly, resulting in near-term dilution from convertible stock issuances but keeping the pipeline active.

Bull CaseUpside scenario

$16.45

The pivotal Phase 3 trial for PF614 meets its efficacy endpoints with superior abuse-deterrent data, and PF614-MPAR successfully completes its Phase 1/2 trials. Ensysce secures a major pharmaceutical partnership or licensing deal through its strategic review, resolving its liquidity issues and Nasdaq compliance risks. The FDA grants accelerated approval under the 505(b)(2) pathway, establishing a new standard of safety in the multi-billion dollar pain management market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary TAAP and MPAR platforms offer chemically built-in abuse and overdose protection, unlike easily manipulated formulation-based deterrents.
PF614-MPAR holds FDA Breakthrough Therapy designation and is backed by multi-million dollar non-dilutive funding from the National Institute on Drug Abuse (NIDA).
Strong global intellectual property portfolio with patents extending protection for key platforms through 2042.

Key Investment Risks

Severe liquidity pressure with only $0.75 million in cash as of March 31, 2026, and a stockholders' equity deficit of -$0.67 million.
High risk of delisting from the Nasdaq Capital Market if the company cannot resolve its stockholders' equity non-compliance.
Substantial dilution risk from the ongoing issuance of shares under convertible preferred stock facilities and warrant exercises.

Thesis Invalidation Triggers

Delisting of ENSC common stock from the Nasdaq Stock Market.
Failure to secure a strategic partner or additional financing by the end of 2026.
Negative clinical data or safety signals in the ongoing PF614-301 Phase 3 trial or PF614-MPAR-102 study.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.